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ABSTRACT
Drug delivery research extensively studies methods to transport proteins, deoxyribonucleic acid (DNA), genes, antibodies, and vaccines efficiently and 
safely to human bodies in recent years. This review comprehensively covers the developments in microneedle-based drug delivery, their configurations, 
design, fabrication, and operation. The factors surrounding the mechanical strength of microneedle-based transdermal patches (MNTP’s) have also 
been reviewed. MNTP’s can eliminate limitations of conventional drug delivery systems. Microneedle-based transdermal delivery approach will offer 
a self-management, patient-friendly, and efficient administration route for drug delivery.
Keywords: Microneedles, Transdermal patches, Insulin, Drug delivery.
INTRODUCTION
Drug delivery research extensively studies methods to transport 
proteins, deoxyribonucleic acid (DNA), genes, antibodies, and vaccines 
efficiently and safely to human bodies in recent years. Conventional 
drug delivery approaches, such as oral administration and hypodermic 
injection, having their own limitations because a drug may be inactive 
through Phase I metabolism during oral delivery [1], while the 
hypodermic injection requires trained personnel [2]. To overcome 
these drawbacks, transdermal drug delivery can be opted as a safe, 
easily accessible, and patient-friendly approach [3]. A significant 
limitation to transdermal drug delivery is the inability of large 
biomolecules to passively diffuse through the dermal layers of skin due 
to their unfavorable hydrophilicity and macro size [4]. Microneedles, 
three-dimensional (3D) microstructures with microscale length 
(usually <1000 μm), can pierce the stratum corneum and generate 
transient microchannels through which external molecules can 
passively diffuse into the skin. Microneedles could be designed in a 
manner that the penetration depth is superficial enough to not touch 
nerve receptors in the lower reticular dermis. This results in a painless 
drug administration. It is promising that this microneedle-based 
transdermal delivery approach will offer a self-management, patient-
friendly, and efficient administration route for drug delivery [5] (Fig. 1).
MICRONEEDLE STRUCTURE AND CONFIGURATION
To ensure efficient drug delivery effect, microneedle chips are 
particularly designed to remain in a specific location; to maintain fluid 
communication with the tissues beneath the subcutaneous layer for an 
extended period of time. This is to remain conducive even when the skin 
is contoured and deformable. Earlier microneedle patches were made on 
a rigid and planar substrate made from silicon, stainless steel, or nickel 
was unable to effectively attach tightly onto the skin surface. Flexible 
microneedle patches have been developed to integrate polymer-based 
microneedles on a flexible substrate to be more pliable to the skin. Since 
fabricating tapered shape is not a standard process in the conventional 
MEMS technology, fabricating tapered microneedles using MEMS 
technology is the most critical part in a flexible microneedle patch [7].
In general, these microneedles can be categorized as solid 
microneedles, drug-coated microneedles, dissolving microneedles, and 
hollow microneedles. As shown in schematically in Fig. 2, each of these 
microneedles enables drug delivery by different mechanisms [8].
Solid microneedles
Solid microneedles are patterned into a sharp geometry which can be 
used to pierce the stratum corneum thus creating microchannels on 
the skin to allow the drug to diffuse through the microchannel. The 
drug is usually loaded onto a flexible substrate under the microneedle 
array. The microneedles penetrate into the skin and drugs uptake by 
capillaries for systemic treatment occurs when the flexible skin patch 
is applied on the skin.
Polymer microneedles
The development of polymer microneedles has focused on providing 
sufficient mechanical strength through different materials, including 
polylactic acid (PLA [9], polymethylmethacrylate [PMMA] [10] and 
maltose [12].
Polymer microneedles are normally patterned with the unconventional 
process due to their tapered 3D structures. The most common way for 
this tapered structure fabrication is inclined ultraviolet (UV) exposure 
technology [13]. When a photomask and a negative thick photoresist 
coated substrate are fixed together, its holding stage is tilted and 
rotated to a UV source. The reflected UV at the interface between the 
resist and the substrate is exploited as well as the incident UV. Except 
UV source, deep X-ray exposure is also deployed to fabricate the 
microneedle structures, known as the lithography, electroplating, and 
molding (LIGA) technique [14].
Due to the low optical absorption rate of the polymers, it can be used 
for the fabrication of polymer microneedles as tall as a few millimeters 
with a high aspect ratio using standard contact lithography equipment, 
which is a challenge in the UV range. Moreover, a two-photon initiated 
polymerization method [15] is utilized to fabricate the microneedles 
structure. A near-infrared ultra-short pulsed laser is focused into a 
photo curable resin to form 3D microstructures. For example, 3D groove-
embedded microneedle has been reported to increase coating formulation 
amounts. To facilitate better drug targeting in the skin and to administer 
liquid coatings microneedles with pocketed structure can be used.
Dissolving microneedles
When compared with coated microneedles, polymer microneedles also 
have been developed in such a way that it can completely dissolve in 
the skin and thereby leave behind no biohazardous sharps waste after 
usage. For the designing of polymer microneedles biocompatible and 
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water soluble materials, such as sugars, are used. And also, the dissolvable 
microneedles can penetrate skin surface as solid microneedles; drugs 
also can be mixed with the microneedle fabrication materials or 
encapsulated inside the microneedles to release into the skin.
Dissolving microneedles usually are fabricated by micro molds. Micro 
molds are filled with melted polymers with specified tapered structure. 
After these polymers are solidified in the mold, microneedles with 
sharp tips are integrated with drug formulations. Various materials 
including carboxymethylcellulose (CMC), chondroitin sulfate 
(polyvinylpyrrolidone, PLA copolymers), and fibroin have been deployed 
to fill into the mold cavities to form microneedles. Since the microneedles 
may not be entirely inserted into the skin, for higher efficiency, the drug 
is desired to be only encapsulated into the multiple-layered microneedles 
or adding an air bubble at the microneedle base tip part. It can be 
achieved by a particle-based molding method forming [17].
Hollow microneedles
Hollow microneedles provide a path for drug delivery into the skin 
or other tissues. The main advantage of hollow microneedles is that 
it allows pressure driven-flow of large dosage solution. Similar to 
conventional hypodermic injections, the pressure applied to hollow 
microneedles [32] can modulate drug flow rate. It enables a rapid bolus 
injection, a slow infusion or a time-varying delivery rate with a single 
flexible microneedle patch.
In general, there are two types of hollow microneedle designs.
• One mimics the traditional hypodermic needle with a single 
microneedle
• The other is an array of multiple hollow microneedle.
The advantage for hollow microneedle array device is that it can deliver.
Liquid formulation to a wide area and also enables a quicker delivery 
than subcutaneous injection. To make polymer hollow microneedles for 
flexible devices [36] have been fabricated directly from a rigid substrate 
using standard MEMS techniques including deep reactive ion etching, 
wet chemical etching and laser micromachining, and innovative 
fabrication methods are used.
By polymerization of liquid resin, a digital micromirror stereolithography 
instrument is used to fabricate hollow polymer microneedles. The 
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Fig. 4: (a-d) Hollow microneedles
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Fig. 3: (a-d) Dissolving microneedles
Fig. 1: Schematic illustration of transdermal drug delivery with 
the drug-containing microneedle array. The array pierces the 
stratum corneum and enables the drugs to enter the epidermis/
dermis layer without reaching the nerve fibers and blood vessels
b
a
Fig. 2: (a and b) Microneedles with different structures and 
configurations
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LIGA technique is utilized to form hollow microneedles by exposing 
X-ray through a mask onto PMMA. Direct low-photon polymerization 
in a laser-based rapid prototyping system is also used to form hollow 
polymer microneedles (Figs. 3 and 4).
Theory of microneedle made by drawing lithography process
To realize a 3D structure, to draw lithography technology is based on the 
viscous property of a polymer in the glass transition is used. The glass 
transition is a kinetic process between a solid state and liquid state of 
an amorphous polymer material. When a melted liquid polymer cools 
down, due to thermal molecular motions, it decreases the amorphous 
portion of the polymer gradually becoming a more viscous and glassy 
liquid. As temperature decreases below Tg, the glassy liquid turns into a 
solid state because of the structural rearrangements with little relative 
mobility (Fig. 5).
When a drawing plate is induced to form microneedles structure, 
drawing lithography is characterized by elastic deformation of polymer 
materials in the glassy transition. Initially, a polymer material with 
glassy state is placed between a substrate and drawing plate.
Subsequently, the polymer with glassy state is elongated by drawing 
the plate. A glassy structure is generated between the substrate and 
substrate. Since the gravitational force and inertial force are negligible, 
the geometry of the glassy structure is mainly modulated by the 
extensional strain force from the drawing plate and the fixed coating 
plate (Fig. 6). This glassy structure is stretched by the drawing plate 
and fixed coating plate from opposite directions. Since the contact area 
with coating plate is much larger than the contact area withdrawing 
plate, the stretching force is stronger from the fixed coating plate. As 
the drawing plate rise up, the glassy structure under the stretching 
force will extensional deform. The radius in the top curvature near the 
drawing plate is smaller than that near the fixed coating plate, which 
induces a wasp-waist shape bridge. As a result of the temperature 
gradient through the glassy structure and change of drawing speed, 
the difference of stretching force in the opposite directions become so 
large that the extension deformation cannot remain a steady-state. The 
breakage of the glassy structure will form a tapered microneedle.
Previously, this drawing lithography process has been applied to 
fabricate 3 types of microneedles: Continuous drawing for an ultra-
high aspect ratio hollow microneedle, stepwise controlled drawing for 
a dissolving microneedle, and drawing with antidromic hybrid electro-
microneedle (Fig. 7).
Microneedle patch design objectives
MNPs seek to achieve multiple design objectives to improve logistics 
and efficiency of drug delivery, as summarized in Table 1.
Fig. 7: Extensional deformation from the fixed coating surface in 
the glass transition. By the axial difference of surface tension, the 
position of narrow necking is situated in the upper part of the 
intermediate liquid bridge
Fig. 6: Viscosity change with temperature and drawing point
Fig. 5: Working principle of microneedle array in transdermal 
patches for transdermal drug delivery
Table 1: Microneedle patch design objectives
Design objects Medical impact
Drug delivered across skin’s 
stratum corneum
Effective drug delivery
Correct dose delivered Effective drug delivery
Targeted delivery to the skin Faster onset of systemic delivery of 
drugs improved immunogenicity of 
vaccines
Reduced expertise needed for 
patch application
Increased access to drug cost 
savings
Improved stability Less reliance and cold chain storage 
and transportation
Reduced or eliminated sharps 
waste
Increased safety reduced need for 
sharps waste disposal
Single-use, single dose, fully 
disposable
Increased safety reduced 
drug/vaccine wastage
No need for reconstitution Increased safety reduced access to 
drug
Lack of pain Improved patient compliance
Delivery feedback Improved patient compliance
Reduced patch wear time Improved patient compliance
Reduced package size Cost savings
Low-cost manufacturing Cost savings
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Drug delivery across skin’s stratum corneum
A primary goal in drug delivery to the skin is diffusion through the 
skin’s outer layer of stratum corneum, which is 10–20 μm thick at 
typical administration sites such as arm and leg transport of drugs into 
the skin. Conventional transdermal patches are limited to a small class 
of drugs that are able to cross the barrier for the drug delivery.
Targeted skin delivery
By the alteration of skin access by different anatomy and physiology, 
the drug efficiency can be altered. For example, the drug administration 
through rich capillary bed in the superficial dermis and effective 
drainage of lymphatic fluids from skin give rapid access of drug to the 
systemic circulation. For the targets for vaccine delivery [71,77], the 
skin is a first line of defense against pathogen entry into the body and, 
therefore, has abundant populations of immune cells. Microneedles are 
measuring hundreds of microns to target the skin, which have 1–2 mm 
thick at typical administration sites.
Reduced expertise needed
MNPs reduce the expertise needed for the administration because 
they are simply pressed to the skin by hand or using a hand-held 
applicator [92,93]. For example, type 1 diabetes is trained to self-inject 
insulin because there is no other therapeutic option, but many type 2 
diabetes is not put on GLP-1 receptor against drugs. The time in which 
when self-administration is not appropriate (e.g., mass vaccination 
campaigns), administration by lesser-trained personnel would increase 
access to otherwise-injectable medicines, which would be especially 
beneficial to the developing countries where trained health-care 
professionals are less in number. Finally, there should be cost savings 
associated with drug administration by lesser-trained personnel.
Improved thermal stability
Many drugs need constant refrigeration, including during 
transportation. This increases costs and complicates logistics, 
especially in developing countries where mechanisms to maintain 
refrigeration from manufacturer to patient (i.e., the “cold chain”) are 
not always intact. In part because of their solid-state formulation, MNPs 
can provide increased stability without refrigeration, especially for 
biomolecules such as proteins and vaccines [98-105].
Reduction or elimination of sharps waste
Hypodermic injection of drugs generates biohazardous sharps waste 
such as used needles. It also poses a safety risk due to transmission 
of diseases by accidental or intentional reuse of needles. It also incurs 
additional costs and requires logistics for safe sharps disposal. Even 
when MNPs are difficult to administer unintentionally, cannot be easily 
reloaded with drug, and generate no sharps waste when water-soluble 
microneedles are used because the microneedles dissolve in the skin.
Use and throw, disposable in nature
MNPs as well as needles [95] and syringes are single use, single dose, 
and fully disposable, all of which reduce the risk of disease transmission 
associated with medical equipment reuse. However, drug and vaccine 
vials are sometimes multiuse and multidose. This can lead to vaccine 
wastage fully disposable MNPs avoid this complexity.
No addition needed
Some drugs are lyophilized to increase stability during storage, but water 
must be added to reconstitute them into a liquid form before injection. 
Reconstitution adds time and complexity and requires expertise to 
prevent potential mistakes with serious medical consequences. MNPs 
capture the stability advantages of a dry formulation and do not need 
to be reconstituted because they are reconstituted ” by the skin’s fluids 
on patch application.
Lack of pain and needle phobia
b
a
Fig. 8: (a and b) Microneedle patch operations
Therapeutic rates, through diffusion. Of suitable drugs are limited 
to  low  molecular  weights  (usually  <350  Da)  and  are  usually 
lipophilic  in  nature.  Hypodermic  needles  very  effectively  cross  the 
stratum  corneum.  Microneedles  measuring  hundreds  of  microns  in 
length  also  effectively  cross  the  stratum  corneum  in  a  minimally 
invasive manner compared to hypodermic injections.
Pain  from  injections  can  be  an  impediment  to  patient  adherence 
with  therapy  [107].  Because  microneedles  are  small,  they  do  not 
hurt and 
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Delivery feedback
Patients generally know when they successfully swallowed a pill or 
completed an injection. Similarly, MNPs would benefit to notify patients 
that the patch has been applied correctly and successfully punctured 
the skin and delivered their payload.
Reduced patch wear time
Swallowing a pill or giving an injection can be completed within 
seconds. Reducing patch wear time would shorten the time 
required to administer the drug and thereby should increase patient 
compliance [110].
Package size small
Pills require little space per dose, but injectable drugs require much 
more space because they contain a large amount of water in addition 
to the active pharmaceutical ingredient. MNPs have no water and have 
reduced needle phobia. Thus, they can be more space efficient, which 
can reduce storage, transportation, and disposal costs.
Low-cost manufacturing
MNPs can be expected to be competitive with injectable drugs in terms 
of manufacturing costs.
MNP design and operation
Microneedles are varying with the design and features even when there 
are several features. They contain an array of thousands of microneedles 
with a sharp tip of 100 to 1000 µm in length. Microneedle can be made 
up of different material such as silicon, metal, or polymer according to 
the type of microneedle and drug is placed on the tip of the needle or 
coated around the microneedle or loaded on the microneedle as the 
type of microneedle such as coated microneedles, hollow microneedles, 
polymer microneedles, and solid microneedles.
Microneedles are mounted as an array on a base substrate, often made 
of the same material as the microneedles. The microneedle array is, 
in turn, attached to a patch backing that often has a skin an adhesive 
to facilitate use. MNP’s can be used in multiple ways for drug delivery 
(Fig. 8). The poke and patch approach involves skin pretreatment by 
puncturing the skin with microneedles that do not contain the drug. 
A drug-loaded patch (or other topical formulation) is then placed over 
the treated area for slow drug release through the residual microneedle 
pores [79,111-113]. The patch may be of a design similar to conventional 
transdermal patches and may incorporate agents to help keep the pores 
open for a longer time to extend the duration of drug delivery [114].
The drug can also be placed in or on the microneedle tip and is then 
actively deposited in the skin on microneedle insertion. In the coat 
and poke approach, the drug is coated on the microneedle surface in 
a water-soluble matrix that dissolves off the microneedles into the 
skin [74,80].
Microneedle patches (MNP) designs and operations.
a. Microneedles comprise a shaft and tip that often encapsulates or 
is coated with a drug. The microneedle array is mounted on a base 
substrate that is attached to patch backing to facilitate handling and 
skin adhesion.
b. Drug delivery approaches for MNP use. MNPs can be used as a 
pretreatment, after which a (i) drug formulation is placed on the 
skin surface for slow drug release through residual pores in the 
skin (poke and patch); (ii) be coated with drug in a water-soluble 
matrix that is released in the skin (coat and poke); (iii) encapsulate 
drug in water-soluble microneedles that dissolve in the skin (poke 
and dissolve); or (iv) encapsulate drug in the patch backing and, in 
some cases, the microneedles that slowly release drug through the 
non-water-soluble microneedle matrix (poke and release).
Various approaches used by the microneedles are:
a. Poke and dissolve approach: It uses microneedles that are water-
soluble and encapsulation of drug within the microneedle matrix 
for the purpose of microneedles to dissolve into the skin and release 
their encapsulated drug.
b. Poke and release approach: With this method, drugs are encapsulated 
in the patch backing and, in some cases, the microneedles to enable 
slow drug release while the patch is adhered to the skin. The patch 
and microneedles are often made of hydrogels that swell on contact 
with the fluids of the skin, thereby enabling the drug to diffuse out 
of the backing through the microneedles and into the skin.
MNP design parameters
There are multiple MNP design parameters that affect patch 
performance, such as microneedle and patch geometry and materials.
Microneedle and patch geometry
The geometry of individual microneedles and the overall patch can 
affect MNP performance. Microneedles are typically 100–1,000 μm 
long. When applied quasi-statically to the skin (e.g., by hand), longer 
microneedles facilitate more reliable skin insertion to overcome skin 
deformation that can result from short microneedles simply bending 
the skin surface without penetrating. However, longer microneedles 
can cause increased pain. Microneedle width (at the base) is typically 
between 50 μm and 300 μm, with aspect ratios ranging between 2:1 and 
10:1. Wider microneedles and smaller aspect ratios provide increased 
strength that prevents microneedle fracture or, more typically, 
deformation. However, wider microneedles are harder to penetrate 
deeply into the skin and can increase pain [60,61]. Some microneedles 
taper continuously from a wide base to a sharp tip, which increases the 
mechanical strength needed to support polymer microneedles [57,62]. 
Other microneedles have parallel walls along much of the shaft and 
then taper only close to the tip. This latter design can often be strong 
enough for metal or silicon microneedles, but sometimes not for 
polymer microneedles.
Microneedle tips are often in the range of 1–10 μm, which is usually 
sufficiently sharp to enable skin insertion. Tips may be less sharp, and 
in some cases (notably for etched silicon microneedles), tip sharpness 
can be well below 1 μm. Microneedles are assembled into arrays that 
typically range from tens to tens of thousands of microneedles. Array 
area is often in the 1–10-cm2 range. This can result in a wide range of 
microneedle densities [37]. A large microneedle density (i.e., requiring 
thinner and, therefore, shorter microneedles) can suffer from the 
“bed-of-nails” effect, where the insertion force is distributed among 
too many microneedles so that none penetrate the skin. This may be 
overcome by having sharper tips and stronger insertion forces. Smaller 
microneedle density makes skin insertion easier and accommodates 
wider and, therefore, longer microneedles, but the smaller number 
of microneedles typically reduces the amount of drug that can be 
delivered. Increasing microneedle array area accommodates more 
microneedles but can increase pain. More importantly, greater array 
area makes microneedle insertion into skin surfaces, which are typically 
non-planar and deformable, more difficult. The overall size of the MNP 
is typically larger than the microneedle array in part to provide an 
additional surface area for the skin adhesive and in part to make the 
patch sufficiently large for easy handling by patients.
MNP materials
MNP must satisfy multiple criteria that vary depending on the patch 
design and among the patch components. The microneedles have to 
be sufficiently strong to puncture the skin. They should also have to 
be biocompatible, which are suitable for manufacturing processes 
and inexpensive. For the non-dissolving microneedles, it is often 
therefore are better accepted by patients. In addition, fear of hypodermic 
needles is widespread and can be a barrier to patients’ accessing health 
care [108]. Since microneedles are typically in a patch form, needle 
phobia should not affect patient acceptance in drug delivery technology.
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accomplished using a metal such as stainless steel and titanium, 
polymers such as polycarbonate and polymethyl methacrylate, polyvinyl 
pyrrolidone, and silicon. The drug is typically present in a water-soluble 
matrix that dissolves in the skin. This matrix is not only biocompatible but 
also suitable for delivery into and clearance from the body. This usually 
means, at a minimum, the matrix must be on the FDA’s. It also should be 
water-soluble and, when rapid onset of drug delivery is desirable, exhibit 
rapid dissolution in the skin. The material should have to be compatible 
with the drug it encapsulates during manufacturing, storage, and 
delivery. When this matrix is used as a coating on microneedles, it must 
form films on the microneedles that remain adherent during storage 
and skin insertion and should be amendable to coating processes. 
When this matrix forms the microneedle (i.e., dissolving microneedles), 
then it must also satisfy the mechanical strength requirement to make 
a strong microneedle. Materials that are often used as water-soluble 
matrices include polymers that help provide mechanical strength and/
or viscosity during coating such as carboxymethyl cellulose, methyl 
cellulose, polyvinyl pyrrolidone [25], polyvinyl alcohol, hyaluronic acid, 
and chondroitin sulfate and can stabilize sensitive biomolecules during 
the manufacturing process.
In some cases, microneedles (and backing) are made of swellable 
hydrogels that release the encapsulated drug on gel hydration. 
Materials such as poly(methyl vinyl ether-comaleic acid) cross-
linked with poly(ethylene glycol) have been used. Work has also been 
done to develop microneedles as slow-release devices made out of 
biodegradable polymers such as polylactic coglycolic acid and silk [67].
Fabrication of MNP’S
The introduced microneedles are silicon microneedles which are 
first prepared at the year 1990. When micro fabrication technology 
had advanced to the point that making microneedle-like structures 
was relatively straightforward. Many additional methods have been 
developed to meet the needs of pharmaceutical manufacturing.
Microneedle structures and molds fabrication
Fabrication of the microneedles is the main part in the MNP 
fabrication [72]. Microneedle structures are often fabricated using 
metal, silicon, or non-dissolving polymer and by poke and patch, as 
well as coat and poke devices. Microneedle structures are also used 
as masters to make molds that are used to fabricate poke and dissolve 
as well as poke and release MNPs.
Silicon microneedles are often made using (deep) reactive ion 
etching [79]. In this method, photolithographic methods are typically 
employed to define the microneedle spacing and base size, and plasma 
chemistry can be adjusted to alter the profile of the microneedle as it 
tapers to a sharp tip. It provides good control over microneedle shape 
but also requires significant method optimization. Reactive ion etching is 
being used to make extremely short (e.g., 100 μm) and sharp microneedle 
arrays for vaccine delivery targeted to the skin’s epidermis [74].
Wet etching of silicon is also used (e.g., in a bath of potassium 
hydroxide), where photolithographic methods, as well as silicon crystal 
planes, define the microneedle shapes [72].
Silicon etching typically produces microneedles pointing out of the 
substrate plane.
Laser cutting has also been used to make microneedles. Similar to wet 
etching, microneedles are made from metal sheets, but the cutting is 
done using an Nd: YAG laser, for example, that “draws” the shapes of 
the microneedles without the need for a mask. Laser-cut microneedles 
often require electropolishing to remove rough edges. Laser ablation 
(e.g., CO2 laser) has also been used to make inverse molds of microneedle 
Polymer microneedles can be made using various methods most 
commonly involving casting liquid solution(s) onto an inverse mold 
of the MNP that is often made of polydimethylsiloxane to dissolving 
microneedles, hydrogel microneedles, and, in some cases, coated 
microneedles. After drying, the MNP is peeled out of the mold. MNPs 
made in this way have been studied for influenza vaccination in clinical 
trials [100,103]. Two-photon polymerization has also been used to 
make polymer microneedles [120].
MNP use
MNP’s are designed in such a way that it has to maintain stability during 
storage, be correctly applied for skin insertion, deliver drug at the right 
dose and kinetics in the skin, and be designed for safe disposal after use.
Drug and vaccine stability in or on microneedles
MNPs need to be stored under conditions that maintain drug activity, 
microneedle integrity (e.g., sharp, strong, and not bent with coating 
intact), and cleanliness (e.g., sterility). This is accomplished not only 
through MNP design but also through packaging that provides physical 
protection from mechanical damage and environmental contamination. 
Storage at appropriate temperature and humidity (e.g., using desiccant) 
also contributes. Drugs have also been studied for their stability when 
formulated into MNPs [91]. Human growth hormone retained most 
of its activity after storage for 15 months at room temperature using 
a CMC/trehalose formulation. Parathyroid hormone formulated in 
sucrose, EDTA, HCl, and polysorbate 20 on coated MNPs was stable for 
2 years without refrigeration, but sterilization by gamma irradiation 
before storage was associated with reduced drug stability over time.
MNP skin application
The complete success of the MNP’s can be achieved by the reliable 
drug delivery with high patient acceptance with less pain. By the slow 
insertion by hand, the skin is highly elastic, which results in significant 
stretch/deformation of the skin before penetration.
The various ways to overcome this limitation include using longer 
microneedles (i.e., approaching 1 mm in length. This approach may, 
therefore, be coupled with having drug only near the microneedle tip, 
so drug toward the base of the microneedle is not wasted because it 
does not enter the skin. A significant advantage is low-velocity insertion 
that it enables hand application of the MNP, which thereby avoids the 
cost, size, and complexity of a high-velocity applicator.
Using shorter microneedles (e.g., 100–300 μm in length) and/or more 
completely penetrating microneedles into the skin requires dynamic 
insertion of the microneedles at high velocity (e.g., 3 m/s) such that 
the higher strain rate of application increases the skin’s instantaneous 
stiffness. Microneedle geometry must also be optimized to allow for 
plastic engagement of the shorter microneedles [123] with the skin, 
which also mitigates the bed of nails effect. A drawback of this approach, 
however, is the necessity of a high-velocity applicator to achieve 
this engagement with the skin consistently. Yet, despite the various 
microneedle designs and insertion devices that have been studied, 
complete microneedle skin insertion is not usually achieved (Fig. 9).
dc
ba
Fig. 9: (a-d) Microneedle patches application in the skin
arrays by “drilling” tapered holes into polymer sheets [132].
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Transport of molecules in the skin after MNP delivery
Following microneedle penetration into the skin, a substantial length of 
the microneedles is suddenly immersed in a wet cellular environment 
within the skin where the dry-formulated drug needs to become wet 
and dissolve. The ideal dissolution characteristics are dependent on 
the desired pharmacokinetics of the drug and its desired mode of 
action within the skin [7,69]. For coated or dissolving microneedles, 
minimizing the amount of time the patch remains on the skin is 
desirable to improve patient acceptance and reduce the likelihood of 
premature patch removal. Between 2 and 20 min are often required, 
although rapid mechanical separation of a drug-loaded “arrowhead” 
from a microneedle shaft has yielded 1-s patch removal times.
Faster drug dissolution times, which correspond to shorter patch wear 
times, may be limited in part by the dissolution characteristics of the 
drug, but can be modulated by the dissolution characteristics of the 
formulation matrix the drug is in. In fact, the drug and formulation 
matrix does not need to be fully dissolved before patch removal; they 
just need to be sufficiently dissolved or hydrated, so the microneedle 
coating or dissolving microneedle matrix remains in the skin when 
the patch is removed. This observation has also enabled formulations 
for extended drug release (even after short patch wear times) because 
formulations deposited in the skin by the microneedles could form a 
depot for slow drug release. Another approach to achieve short patch 
wear times is to minimize the amount of material to be dissolved and 
gives it a large surface-to-volume ratio. This can be achieved by thinner 
microneedles or microneedle coatings but often needs to be balanced 
with delivering a given dose, which may call for larger masses of drug 
and excipient [62]. Once the drug has dissolved in the skin, it diffuses 
away from the site of delivery. For systemic uptake in the bloodstream, 
the drug should most likely diffuse to capillaries. Since capillaries are 
in high abundance in the superficial dermis, rates of uptake for various 
drugs after MNP administration are faster compared with rates after 
subcutaneous injection. In contrast, vaccine delivery is often targeted 
to the skin’s abundant resident immunological cells, so rapid diffusion 
away from the site of administration may not be desirable. This type of 
skin vaccination has enabled improved immune responses (compared 
with standard needle and syringe injection into a muscle), as shown by 
vaccine dose sparing [65], greater longevity of immunity, and greater 
breadth of immunity. The ideal deposition site and duration of vaccine 
residence in the skin are not fully understood and remain subjects of 
investigation.
Disposal of MNP patch
In some cases, when the drug delivery is not 100% efficient the safe 
disposal of microneedle patches important which is coming into the 
category of residual drug, biohazards, and sharp waste. However, in 
that cases, there may be dangers of residual drug exposure to others, 
including children, animals, and the environment, or there may be illicit 
use of the residual drug if, for example, it is a drug of addiction. Used 
MNPs are likely considered biohazardous waste because they contact 
bodily fluids like interstitial fluid of the skin. However, the amount of 
bodily fluid is probably small which is even less than the blood found 
on a used adhesive bandage. Used MNPs are considered sharps waste. 
Dissolving MNPs are likely not considered sharps waste because they 
contain no microneedles after use. Nondissolving such as coated 
microneedles may be considered sharps waste, although the hazard 
they pose is different from that of used hypodermic needles or scalpel 
blades and may, therefore, be handled differently. In all these cases, 
safe disposal may be facilitated through suitable waste streams such 
as placement in sharps containers or biohazard bags and/or through 
suitable packaging after use.
Drug/vaccine MNP delivery outcomes in terms of 
pharmacodynamics or pharmacokinetics
MNPs have been developed for delivery of dozens of different drugs in 
preclinical studies, and a few of them have been evaluated in clinical 
trials. Most studies have compared that the pharmacokinetics and 
pharmacodynamics of drug delivery to the skin are using MNPs to drug 
delivery to the muscle or subcutaneous space by hypodermic injection. 
The objective of either has been to show the similarity between the 
two routes of administration or improvements such as faster uptake of 
drug into the bloodstream, increased vaccine immunogenicity which is 
enabled by the MNP.
Vaccines
In addition to logistical and delivery advantages, MNP vaccination also 
offers improved immunogenicity [75-77]. Skin vaccination using MNP 
targets resident immune cells, such as epidermal Langerhans cells and 
dermal dendritic cells, and can be enhanced by circulating immune 
cells recruited to the site. There is also extensive fluid transport from 
the skin to the draining lymph nodes. Slow release of vaccines also 
increases immunogenicity.
The studies are going on in MNP vaccines such as diphtheria, 
chikungunya, and anthrax. These vaccines have also been immunogenic 
in animal models, including mice, rats, guinea pigs, rabbits, pigs, and 
macaques. The immune responses from both human and cellular have 
been measured which are often show a proof, of which is superior to 
hypodermic injection. Some vaccination literature has emphasized 
the use of extremely dense arrays of microneedles (e.g., 10,000/cm2) 
designed to kill cells in the epidermis at the site of each microneedle 
penetration. This approach deposits the vaccine in a local milieu of 
immunogenic signals released from dying and dead cells which can 
further enable significant vaccine dose control over the body by the 
MNP’s [76-80].
Drugs
Although vaccines have received more attention in the literature, 
small-molecule and peptide drugs have progressed further into clinical 
translation.
Drugs have also been administered for local effects. These include 
drugs for photodynamic therapy and local skin anesthesia and also 
phenylephrine to treat fecal incontinence through local delivery near 
the anal sphincter.
Biotherapeutics have been administered using MNPs. Insulin has 
received considerable attention for bolus, basal, and glucose-
responsive delivery to the skin. Other peptide and protein drugs include 
erythropoietin, heparin, leuprolide acetate, desmopressin, and human 
growth hormone [96]. Additional studies have administered plasmid 
DNA and small interfering RNA using MNPs.
Pharmaceutical
Safety
The development of MNP’s is mainly occurred for the increased safety 
purposes. However, from the safety profiles from clinical trials and 
other human studies typically show only mild, transient erythema at 
the site of patch application as the most common side effect. Numerous 
studies have shown that microneedles cause little or no pain in human 
MNP’s  playing  a  major  role  in  the  field  of  the  medical  field  but  it 
also  has  applications  in  the  cosmetic  types  also.  The  first 
microneedle  is  cylindrical.  The  original  purpose  of  these 
devices was to promote collagen production in the skin in 
response to the micro-injuries caused by the microneedles and 
thereby improve skin.  They can be marketed in combination 
with  topical  formulations,  for  example,  for  microneedle 
pre-treatment that facilitates entry of materials applied to 
the skin.  Dissolving microneedles made of  hyaluronic acid 
have  also  been  marketed  for  cosmetic  purposes.  On  the  basis  of 
the  success  of  intradermal  hyaluronic  acid  injections  used as 
fillers  to  combat  the  effects  of  aging  on  the  skin.  These 
products entered the marketplace more than 10 years ago and are
 gaining popularity. Such pharmaceutical products can eventually 
be  integrated  into  the  digitalization  and  automation  processes 
involved in drug discovery and manufacture [125].
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subjects. The possibility of infections occurring at the site of MNP 
application has received only limited attention, but infections have not 
been reported in human studies. Cosmetic microneedle roller devices 
are used repeatedly by the same person and are not sterilized between 
uses; this practice does not appear to cause infection, although no 
studies have been performed to look specifically at this question. Even 
when MNP’s generate sharp waste; they may be less hazardous than 
hypodermic needles.
Characterization studies
Mechanical strength of the microneedles
To study the mechanical strength of the MNP’s, both the adequate 
adhesion property between the tip and microtubes, and the sufficient 
stiffness of the microtubes for successful penetration, were studied. As 
shown in Fig. 10a, Instron Microtester 5848 (Instron, USA) was used 
for the stiffness testing. A typical result was shown in Fig. 10b. During 
the testing, the breakage of microneedles only occurred at the interface 
when the exerting load was larger than the threshold value. However, 
the SU-8 microtubes were strong enough to stand the pressure. After 
characterization of 20 samples, the average threshold value was 
7.36±0.48 N for the microneedles (300 μm at microneedle base and 
1000 μm high). Since the minimal force required for a successful 
penetration was reported to be <1 N with the similar microneedle 
dimension [54], the device was reliable during the penetration process.
Characterization of penetration (Fig. 11)
To check whether the maltose tips could be dissolved once inserted in 
the tissue, four chips with the same maltose tips height were inserted 
into the skin and taken out one by one with 3 min interval. Maltose tips 
were gradually dissolved versus increased time as shown in Fig. 12b. 
After 9 min, the maltose tips were totally dissolved, and the lumens 
of SU-8 microtubes were observed from the top view. Different from 
the traditional dissolvable needles which encapsulated drugs into the 
needles, this microneedle array was expected to allow large volume of 
drugs to pass through the remaining SU-8 microtubes inside the skin.
Blue dyed water was ejected through the lumens in microneedle to 
the beaker containing fresh water such that we could demonstrate 
the hollow microneedle formed in individual microtube during the 
fabrication process. This microfluidic testing was performed in fresh 
water as shown in Fig. 13. Visual inspection of the ejection proved that 
there was no blockage inside the microtubes. Due to the good bonding 
quality between each layer, there was no obvious damage on the device 
in this experiment even though the syringe pump was increased to its 
maximum speed at 3.3 mL/min for 6 mL syringe.
To verify that the drug solution can be delivered into tissue, a fluorescent 
solution was delivered through the microneedles after the insulin were 
dissolved. The representative results were then investigated through a 
ba
Fig. 11: (a and b) Penetration testing results on the porcine 
cadaver skin
ba
Fig. 10: (a) Testing setup for the microneedle mechanical testing. 






Fig 13: (a-f) Microfluidic testing for SU-8 microtubes
dc
ba
Fig. 12: Maltose tips dissolving process. (a) The original sharp 
maltose tip. (b) Maltose tip after inserted into skin for 3 min 
(c) 6 min and (d) 9 min
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confocal microscopy (Fig. 14). The permeation pattern of the solution 
along the microchannel confirms the solution delivery results. The black 
area served as a control area without any diffused solution. In contrast, 
the tissues stained by fluorescence illustrated the diffused area. The 
focus depth was up to 180 μm with the interval of 30 μm. Since the 
microchannel was created by the conical shaped tips, the diameter of 
the microchannel decreased as the focus depth increases. The following 
diffusion area was dependent on the microchannel dimension and also 
decreased accordingly Mironeedles penetrate parafilm and collagen 
hydrogel to subsequently deliver drugs with controlled pressure and 
electric field (Figs. 15 and 16).
In the test of glucose delivery, glucose solution was delivered into the 
collagen slab under different pressure and duration. Then, the collagen 
slabs were digested in 1mg/mL collagenase at room temperature. 
It will take around 1 h for all the collagen slabs to be fully digested. 
The solution was collected to measure the glucose concentration with 
glucose detection kit. By comparing the readings from the kit with 
the measured concentration standard curve, the concentration of the 
glucose in hydrogel was measured. Such studies are crucial to the 
evaluation of Diabetes patients [126,127].
CONCLUSION
MEMS is a rapidly growing in its range of applications, particularly in 
the medical field. Microneedle-based transdermal patches (MNTP) 
are an example. Microneedles are 3D microstructures with microscale 
length of usually <1000 μm. They can pierce the stratum corneum and 
generate transient microchannels through which external molecules 
can passively diffuse into the skin. MNTP’s can eliminate the limitations 
of conventional drug delivery systems. Microneedle-based transdermal 
delivery approach will offer a self-management, patient-friendly, and 
efficient administration route for drug delivery.
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